Unique ID issued by UMIN | UMIN000031477 |
---|---|
Receipt number | R000035931 |
Scientific Title | A Phase II study of laparoscopic gastrectomy for advanced gastric cancer with neoadjuvant chemotherapy |
Date of disclosure of the study information | 2018/04/27 |
Last modified on | 2019/03/26 10:34:30 |
A Phase II study of laparoscopic gastrectomy for advanced gastric cancer with neoadjuvant chemotherapy
A Phase II study of laparoscopic gastrectomy for advanced gastric cancer with neoadjuvant chemotherapy
A Phase II study of laparoscopic gastrectomy for advanced gastric cancer with neoadjuvant chemotherapy
A Phase II study of laparoscopic gastrectomy for advanced gastric cancer with neoadjuvant chemotherapy
Japan |
Advanced gastric cancer with with neoadjuvant chemotherapy
Gastrointestinal surgery |
Malignancy
NO
To evaluate the safety of laparoscopic gastrectomy for advanced gastric cancer with neoadjuvant chemotherapy.
Safety
Phase II
Grade 3 or higher surgical complications (Clavien-Dindo Classification)
All surgical complications (Clavien-Dindo Classification), recurrence-free survival,over all survival, proportion of conversion to open surgery,number of retrieved lymph node, postoperative hospital stay, completion rate of adjuvant chemotherapy,
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Maneuver |
Laparoscopic gastrectomy
20 | years-old | <= |
80 | years-old | > |
Male and Female
(1)Histologically proven gastric carcinoma (including esophago-gastric junctional cancer)
(2)Prior treatment of chemotherapy for gastric cancer
(3)R0 resection or R1 resection solely by CY1 can be obtained
(4)Aged 20 to 79 years
(5) Eastern Cooperative Oncology Group (ECOG) PS of 0-2
(6) No obvious organ failures and satisfy the following laboratory data within 30 days before registration:
WBC >=2,000/mm3 WBC<15,000/mm3
Platelet >= 50,000/mm3
Hb >= 8.0 g/dL
AST <= local reference range 5
ALT <= local reference range 5
T.Bil <= 3.0 mg/dL
Creatinin <= 2.0 mg/dL
(7)Provided written informed consent
(1)Active infection disease
(2)Over 38.0 degree Celsius
(3)Severe mental disease.
(4)Continuous systemic steroid therapy.
(5)History of myocardial infarction or unstable angina pectoris within six months.
(6)Uncontrollable hypertension.
(7)Uncontrollable diabetes millutus or administration of insulin.
(8)Severe respiratory disease requiring continuous oxygen therapy.
(9)Kidney failure requiring hemodialysis or peritoneal dialysis
(10)Patients who are currently participating in an interventional study that strongly influences this study.
(11)Other unfeasible factors to perform study safely approved by attending surgeon.
50
1st name | |
Middle name | |
Last name | Yukinori Kurokawa |
Osaka University School of Medicine
Gastroenterological Surgery
2-2 Yamadaoka Suita City Osaka
06-6879-3251
ykurokawa@gesurg.med.osaka-u.ac.jp
1st name | |
Middle name | |
Last name | Atsushi Gakuhara |
Osaka University School of Medicine
Gastroenterological Surgery
2-2 Yamadaoka Suita City Osaka
06-6879-3251
agakuhara@gesurg.med.osaka-u.ac.jp
Department of Gastroenterological Surgery, Osaka University School of Medicine
Department of Gastroenterological Surgery, Osaka University School of Medicine
Self funding
NO
2018 | Year | 04 | Month | 27 | Day |
Unpublished
Open public recruiting
2018 | Year | 04 | Month | 25 | Day |
2018 | Year | 04 | Month | 27 | Day |
2018 | Year | 02 | Month | 26 | Day |
2019 | Year | 03 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035931